A Clinical trial on viswathiya choornam in the management of uthiravatha suronitham( Rheumatoid Arthritis)

A PROSPECTIVE OPEN LABELLED, SINGLE ARM, NON- RANDOMIZED, SINGLE CENTRIC, PHASE II CLINICAL TRIAL TO DETERMINE THE EFFECTIVENESS OF VISWATHIYA CHOORNAM IN THE MANAGEMENT OF UTHIRAVATHA SURONITHAM (RHEUMATOID ARTHRITIS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052317

Enrollment

Registered

2023-05-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement Health Condition 2: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: VISWATHIYA CHOORANAM: DOSAGE: 3-5 GRAMS WITH GHEE (per day) Frequency: 1-2grams (BDS) Route: Oral Days of intervention: 45 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1.Those who are willing to participate in the study. 2.RA factor test : positive 3.Anti CCP test :positive 4.CRP Test 5. DAS score 28 >2.6

Exclusion criteria

Exclusion criteria: 1.Age: Below 34 ; Above 60 2.Other degenerative joint disease like osteoarthritis, sero negative spondyloarthritis, ankylosing spondylitis. 3.Infectious joint disease like tuberculosis,chronic poly arthritis in chickungunia viral infection. 4.Metabolic joint disease 5.Pregnancy and lactating mothers 6.Chronic renal and liver disease patients.

Design outcomes

Primary

Measure	Time frame
1.Symptomatic relief i.e, reduction in pain, swelling, movement difficulties(DAS score) 2.Improve the physical movements and relieve the disabilities and structural defects of hand and legs as much as possible 3.Reduce any extra articular involvement of the disease if any. Timepoint: 45 days	—

Secondary

Measure	Time frame
1.Prevent recurrence of the disease by advising, continuous and periodic intake of medicine and dietary regimen. 2.Proper monitoring of patient and disease state with relevant blood test and immunological assays. 3.To collect various Siddha literatures and modern journals for literature review on UTHIRAVATHA SURONITHAM. 4. To perform physicochemical, phytochemical, bio chemical analysis 5.To evaluate safety profile for acute and sub-acute toxicity 6.To evaluate pharmacological activities 7.To perform in-vitro, in-vivo studies. 8.To evaluate anti microbial activity 9.To perform cell line studies 10.To evaluate Siddha parameters (including Envagai thervu, Neerkuri-Neikuri) in uthiravatha suronitham during trial period. 11.To evaluate modern parametric changesTimepoint: 6 months	—

Measure

Time frame

1.Prevent recurrence of the disease by advising, continuous and periodic intake of medicine and dietary regimen. 2.Proper monitoring of patient and disease state with relevant blood test and immunological assays. 3.To collect various Siddha literatures and modern journals for literature review on UTHIRAVATHA SURONITHAM. 4. To perform physicochemical, phytochemical, bio chemical analysis 5.To evaluate safety profile for acute and sub-acute toxicity 6.To evaluate pharmacological activities 7.To perform in-vitro, in-vivo studies. 8.To evaluate anti microbial activity 9.To perform cell line studies 10.To evaluate Siddha parameters (including Envagai thervu, Neerkuri-Neikuri) in uthiravatha suronitham during trial period. 11.To evaluate modern parametric changesTimepoint: 6 months

—

Countries

India

Contacts

Public ContactProfDrAManoharan

GOVERNMENT SIDDHA MEDICAL COLLEGE, PALAYAMKOTTAI

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026